Technical Analysis for MRSN - Mersana Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 19.455 5.62% 1.04
MRSN closed up 5.62 percent on Friday, September 25, 2020, on approximately normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical MRSN trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Wide Bands Range Expansion 0.00%
MACD Bearish Signal Line Cross Bearish 5.62%
Calm After Storm Range Contraction 5.62%
Wide Bands Range Expansion 5.62%
Down 3 Days in a Row Weakness 5.62%
Down 4 Days in a Row Weakness 5.62%
Down 5 Days in a Row Weakness 5.62%
Fell Below 20 DMA Bearish 2.50%
Fell Below 50 DMA Bearish 2.50%
Older End-of-Day Gignals for MRSN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High 2 days ago
Up 5% 2 days ago
60 Minute Opening Range Breakout 2 days ago
Up 3% 2 days ago
Up 2% 2 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
Medicine Biotechnology Cancer Immunology Cancers Monoclonal Antibodies Chemotherapy Antibody Drug Conjugates Adc Synaffix

Is MRSN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 26.64
52 Week Low 1.32
Average Volume 959,197
200-Day Moving Average 12.98
50-Day Moving Average 19.85
20-Day Moving Average 19.93
10-Day Moving Average 21.85
Average True Range 2.00
ADX 20.76
+DI 21.67
-DI 19.17
Chandelier Exit (Long, 3 ATRs ) 20.65
Chandelier Exit (Short, 3 ATRs ) 21.44
Upper Bollinger Band 25.15
Lower Bollinger Band 14.72
Percent B (%b) 0.45
BandWidth 52.34
MACD Line 0.29
MACD Signal Line 0.49
MACD Histogram -0.2011
Fundamentals Value
Market Cap 441.88 Million
Num Shares 22.7 Million
EPS -16.23
Price-to-Earnings (P/E) Ratio -1.20
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.78
Resistance 3 (R3) 21.57 20.59 21.39
Resistance 2 (R2) 20.59 20.00 20.70 21.26
Resistance 1 (R1) 20.02 19.63 20.31 20.23 21.13
Pivot Point 19.04 19.04 19.18 19.15 19.04
Support 1 (S1) 18.47 18.45 18.76 18.68 17.78
Support 2 (S2) 17.49 18.08 17.60 17.65
Support 3 (S3) 16.92 17.49 17.52
Support 4 (S4) 17.13